BioSpace News Archive

Pharmascience Canada is proud to launch PRpms-ONDANSETRON ODT tablets in 4 mg and 8 mg!

Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN).

The increasing presence of vast telemedicine providers is projected to add a boost to the growth of the global telemedicine market.

Albany NY, United States: New approaches for ocular drug delivery have expanded the horizon for ophthalmic drugmakers.

Albany NY, United States: A functioning nurse call system is rightly considered a lifeline between medical staff and patients.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery annual meeting, which will take place from April 22-26, 2022 in Washington, D.C.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, announced Aaron Osborne, MBBS, was appointed Chief Medical Officer and Chief Development Officer.

Castle Biosciences, Inc. announced a recent poster presentation highlighting data and concluding that its non-invasive skin scraping technique produces sufficient ribonucleic acid to assess reproducible gene expression for its inflammatory skin disease pipeline test.

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, announced that it has raised a $40 million intellectual property-based debt solution to fund growth led by GT Investment Partners with support from Aon plc.

Ocugen, Inc. today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico.